Sljedeći

Auto Play

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

1 Pogledi • 07/18/23
Udio
Ugraditi
administrator
administrator
Pretplatnici
0

William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.

Prikaži više
0 Komentari sort Poredaj po
Komentari na Facebooku

Sljedeći

Auto Play